Har­poon's fall con­tin­ues as CMO de­parts weeks af­ter lead pro­gram axed

With the lead clin­i­cal pro­gram out the door last month, Har­poon Ther­a­peu­tics’ chief med­ical of­fi­cer is al­so ex­it­ing the small biotech that has had lit­tle good news since June 2021.

Na­tal­ie Sacks told the South San Fran­cis­co biotech on Tues­day that she would re­sign as of June 1, ac­cord­ing to an SEC fil­ing and press re­lease from Thurs­day af­ter mar­ket close. Har­poon’s stock $HARP fell al­most an­oth­er 10% af­ter the clos­ing bell Thurs­day, falling be­low $5 a share, once again.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER